ALCAM (CD166) expression and serum levels in pancreatic cancer

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Tachezy, Michael ^a   Zander, Hilke ^a   Marx, Andreas H ^a   Stahl, Phillip R ^a   Gebauer, Florian ^a   Izbicki, Jakob R ^a   Bockhorn, Maximilian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BIOLOGICAL MARKER;

ADULT; AGED; ALCAM GENE; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHRONIC PANCREATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PANCREAS CANCER; PRIMARY TUMOR; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL ADHESION MOLECULES, NEURONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC;

EID: 84862705612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039018     Document Type: Article

References (47)

1. Li D, Xie K, Wolff R, Abbruzzese JL, (2004) Pancreatic cancer. Lancet 363: 1049-1057.
2. Kleeff J, Friess H, (2008) Nonmetastatic pancreatic cancer: many trials, little progress. J Clin Oncol 26: 3100; author reply 3100-a-3101.
3. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
4. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M, (2009) Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335-339.
5. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, et al. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610.
6. Mehta SP, (2010) Palliative chemotherapy for pancreatic malignancies. Surg Clin North Am 90: 365-375.
7. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, et al. (2006) Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 49: 241-244.
8. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327.
9. Boman BM, Huang E, (2008) Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838.
10. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104: 10158-10163.
11. Pardal R, Clarke MF, Morrison SJ, (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
13. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, et al. (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148: 259-272.
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A, (2009) Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27: 844-850.
16. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
17. Piscuoglio S, Lehmann FS, Zlobec I, Tornillo L, Dietmaier W, et al. (2011) Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. J Clin Pathol.
18. Ofori-Acquah SF, King JA, (2008) Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 151: 122-128.
19. Weidle UH, Eggle D, Klostermann S, Swart GW, (2010) ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 7: 231-243.
20. van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, et al. (2008) Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 68: 3671-3679.
21. Swart GW, (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81: 313-321.
22. Buhusi M, Demyanenko GP, Jannie KM, Dalal J, Darnell EP, et al. (2009) ALCAM regulates mediolateral retinotopic mapping in the superior colliculus. J Neurosci 29: 15630-15641.
23. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, et al. (2007) Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med 85: 1113-1123.
24. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, et al. (2007) Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 6: 2737-2746.
25. Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, et al. (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112: 419-427.
26. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G, (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164.
27. Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, et al. (2011) Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 42: 1946-1952.
28. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, et al. (2008) Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14: 1726-1733.
29. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101: 457-464.
30. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, et al. (2011) ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer.
31. Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, et al. (2011) ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 170: 226-232.
32. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, et al. (2012) Activated leukocyte cell adhesion molecule (CD166)-Its prognostic power for colorectal cancer patients. J Surg Res.
33. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, et al. (2007) The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253.
34. Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S, (2009) Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 24: 2143-2148.
35. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, et al. (2009) Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 125: 9-14.
36. Ladd J, Taylor AD, Piliarik M, Homola J, Jiang S, (2009) Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 393: 1157-1163.
37. Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, et al. (2010) ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol 101: 564-569.
38. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: e123.
39. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, et al. (2003) ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54: 34-43.
40. Simon R, Mirlacher M, Sauter G, (2010) Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 664: 113-126.
41. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG, (2007) Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15: 124-133.
42. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21: 1371-1378.
43. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, et al. (2010) Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 139: 2072-2082 e2075.
44. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, et al. (1986) Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 90: 343-349.
45. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, et al. (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8: 113-117.
46. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, et al. (2010) 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer 49: 569-575.
47. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, et al. (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129.